BridgeBio Pharma, Inc. (BBIO) vs Exelixis, Inc. (EXEL)

BridgeBio Pharma, Inc. and Exelixis, Inc. are both Biotechnology companies. BridgeBio Pharma, Inc. and Exelixis, Inc. are of similar size ($14.4B and $13.1B). BridgeBio Pharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Exelixis, Inc. trades at 17.6×. BridgeBio Pharma, Inc. grew revenue faster over the last twelve months: 202.4% against 9.23%. Exelixis, Inc. has the higher net margin (35.3% vs −97.0%) and the higher return on invested capital (60.5% vs 0.00%). Across the 18 metrics below, Exelixis, Inc. leads on 14 and BridgeBio Pharma, Inc. on 4.